Board of Directors

B-MoGen partners with top leaders who have extensive experience in biotechnology business and science to help guide and govern our rapidly growing company.

Mike Rusinko B-MoGen

Mike Rusinko

Mike Rusinko is a creative business executive who has worked for and with some of the premier brands in the world. In his nearly thirty years with Accenture, Rusinko has led and managed regional and global efforts that have focused on driving revenue growth by transforming business practices and building enduring relationships. Rusinko brings the best practices of a globally renowned professional services firm and combines that with the heart of an entrepreneur. The combination results in creative and practical solutions to complex business challenges across a wide variety of industries. Rusinko’s engaged management style is a large reason for his success as are his commitment to team and professionalism. These attributes have resulted in his ability to work across the expanse of Accenture’s extensive business offerings, global operations and client base.

Dave Eansor

Dave Eansor, MBA

Effective October 19th, 2018, Dave Eansor became a member of the Board of Directors of Marker Cell Therapy (a public, pre-revenue therapeutics company) and Chairman of the Audit Committee.

Effective July 1st, 2018, Mr. Eansor has been promoted to President of the Protein Sciences Segment. He has P&L responsibility for over 2/3rds of Bio-Techne. In addition to his current responsibilities in leading the Biotech Division, David also assumed responsibility for the Protein Platforms Division. David remains a Sec.16 Officer at Bio-Techne

From April, 2015 to July 1st, 2018, Mr. Eansor was the Sr. Vice President of the Biotech Division. He had P&L responsibility for the largest division of the company which includes the R&D Systems, Novus and Tocris brands of Assays, Proteins, Antibodies, Sm. Molecules and Cell Culture products.

Prior to joining Bio-Techne, David was the Sr. Vice President of Corporate Development for Novus Biologicals, LLC which was acquired by Bio-Techne on July 2nd, 2014. Immediately following the acquisition he became Sr. Vice President of Novus Biologicals. His primary responsibility was to act as the General Manager for the legacy Novus business and the integration lead.

Prior to joining Novus, Mr. Eansor was the President of the Bioscience Division of Thermo Fisher Scientific. At the time, the Bioscience Division included the Life Science Research (LSR) businesses, the Bioprocess Production business and the Global Chemicals business of Thermo. David was promoted to Division President in early 2010 after 5 very successful years as President of Thermo Fisher’s Life Science Research business which included the Genomics, Proteomics and Cellomics business units.

Prior to joining Thermo Fisher Scientific, David spent 5 years as President of Cambrex Bioproducts where he was responsible for the Media & Serum, Microbiology, Cell Therapy and Research Products business units of Cambrex Corporation.

Prior to joining Cambrex, Mr. Eansor spent 19 years with R. P. Scherer Corporation, a contract pharmaceutical drug delivery manufacturer which was acquired by Cardinal Health. There he held various senior management positions, the last of which was Vice President of Pharmaceutical Operations.

David has a BSc in Chemistry from University of Western Ontario, a Bachelor of Commerce in General Business and Economics, and an MBA from the University of Windsor, Ontario, Canada.

Erwin A. Kelen

Erwin A. Kelen

Erwin Kelen has been a full-time venture capitalist and angel investor for the past 25 years. He was a principal of the Quatris Fund, an early stage VC firm. He is the founder of Kelen Ventures, a business development and private investment firm. He has been involved in the formation, financing, growth and sale of many firms in the areas of technology, medical devices, and financial services.

Previously, he was the President and CEO of DataMyte Corporation, a factory automation hardware and software manufacturer. He was also Chairman and CEO of Electro-Craft Corporation, a manufacturer of DC servomotors and controls. Allen Bradley/Rockwell International acquired both companies.

Over the past 45 years, Mr. Kelen has served as director of several public and private companies, ranging from early stage development companies to firms listed on the New York Stock Exchange. He is also active in community affairs and serves on the Boards of the University of Minnesota Foundation and the Saint Paul Chamber Orchestra.

Mr. Kelen holds an undergraduate degree from the Technical University of Budapest, Hungary, and a Master’s degree in electrical engineering from the University of Minnesota, Minneapolis, MN.

David A. Largaespada, Ph.D. B-MoGen

David A. Largaespada, Ph.D.

Chairman, Scientific Advisory Board

Dr. Largaespada is an authority on mouse genetics, gene modification, cancer genes, and disease models. His outstanding background was integral to the founding of B-MoGen Biotechnologies, Inc. He spent five years as a postdoctoral fellow in Frederick, Maryland at the National Cancer Institute working with world-renowned geneticists Dr. Nancy Jenkins and Dr. Neal Copeland, where the Leukemia and Lymphoma Society of America awarded him a postdoctoral fellowship. He is currently a Full Professor in the Department of Pediatrics and the Department of Genetics, Cell Biology and Development at the University of Minnesota.

Jeff S. Liter, MBA B-MoGen

Jeff S. Liter, MBA

President and CEO

Jeff is a senior executive with a proven track record at profitably growing emerging companies and business divisions. His experience developing businesses to 1st and 2nd market positions, raising over $3.2 million for prior start-ups, and leading start-to-finish M&A transactions from $4 million to over $2 billion. Jeff comes to B-MoGen after serving for two years as COO of a cGMP cellular therapy company where in his first year he completed a turnaround of their CDMO services to its’ first ever profitable status. As the business leader in B-MoGen Biotechnologies, Jeff aims to enable the company to become an industry leader in gene editing.